Evidence map›Paper›PMID 31417259›Full record

ArticleInternational journal of nanomedicine2019

α-synuclein interaction with zero-valent iron nanoparticles accelerates structural rearrangement into amyloid-susceptible structure with increased cytotoxic tendency.

Seyedeh Sahar Tahaei Gilan, Dorsa Yahya Rayat, Twana Ahmed Mustafa, Falah Mohammad Aziz, Koorosh Shahpasand, Keivan Akhtari, Abbas Salihi, Osama K Abou-Zied, Mojtaba Falahati

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in pharmacology · 2022
    Review
  7. Article
  8. Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Seyedeh Sahar Tahaei Gilan *Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Dorsa Yahya Rayat *Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Twana Ahmed MustafaDepartment of Medical Laboratory Technology, Health Technical College, Erbil Polytechnic University, Erbil, Kurdistan Region, Iraq.
Falah Mohammad AzizDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Koorosh ShahpasandDepartment of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Keivan AkhtariDepartment of Physics, University of Kurdistan, Sanandaj, Iran.
Abbas SalihiDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Osama K Abou-ZiedDepartment of Chemistry, Faculty of Science, Sultan Qaboos University, P.O. Box 36, Postal Code 123 Muscat, Oman.
Mojtaba FalahatiDepartment of Nanotechnology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Islamic Azad University Medical Branch of Tehran · IRSalahaddin University-Erbil · IQRoyan Institute · IRSulaimani Polytechnic University · IQSultan Qaboos University · OMUniversity of Kurdistan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIt has been indicated that NPs may change the amyloidogenic steps of proteins and relevant cytotoxicity. Therefore, this report assigned to explore the impact of ZVFe NPs on the amyloidogenicity and cytotoxicity of α-synuclein as one of the many known amyloid proteins.

methodsThe characterization of α-synuclein at amyloidogenic condition either alone or with ZVFe NPs was carried out by fluorescence, CD, UV-visible spectroscopic methods, TEM study, docking, and molecular modeling. The cytotoxicity assay of α-synuclein amyloid in the absence and presence of ZVFe NPs was also done by MTT, LDH, and flow cytometry analysis.

resultsThT fluorescence spectroscopy revealed that ZVFe NPs shorten the lag phase and accelerate the fibrillation rate of α-synuclein. Nile red and intrinsic fluorescence spectroscopy, CD, Congo red adsorption, and TEM studies indicated that ZVFe NP increased the propensity of α-synuclein into the amyloid fibrillation. Molecular docking study revealed that hydrophilic residues, such as Ser-9 and Lys-12 provide proper sites for hydrogen bonding and electrostatic interactions with adsorbed water molecules on ZVFe NPs, respectively. Molecular dynamics study determined that the interacted protein shifted from a natively discorded conformation toward a more packed structure. Cellular assay displayed that the cytotoxicity of α-synuclein amyloid against SH-SY5Y cells in the presence of ZVFe NPs is greater than the results obtained without ZVFe NPs.

conclusionIn conclusion, the existence of ZVFe NPs promotes α-synuclein fibrillation at amyloidogenic conditions by forming a potential template for nucleation, the growth of α-synuclein fibrillation and induced cytotoxicity.

Indexed as

alpha-SynucleinAmyloidBenzothiazolesCell DeathCell Line, TumorCongo RedHumansIronKineticsL-Lactate DehydrogenaseMetal NanoparticlesMolecular Docking SimulationMolecular Dynamics SimulationOxazinesProtein AggregatesProtein Structure, Secondaryalpha-SynucleinAmyloidBenzothiazolesCongo RedIronL-Lactate Dehydrogenasenile redOxazinesProtein Aggregatesthioflavin TTyrosineamyloidcytotoxicityspectroscopyZVFe NPα-synuclein

Identifiers

PMID31417259
PMCPMC6602305
OpenAlexW2955783203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.